Future studies using amyloid- and tau-PET will investigate these potential associations between molecular pathology and navigational behaviour in the early stages of Alzheimer’s disease further, and the relative contribution of amyloid-β and tau to the observed behavioural deficits. The gene discussed is MAPT; the disease is Alzheimer disease.